Ballew Advisors’s Exact Sciences EXAS Stock Holding History

Ballew Advisors’s Portfolio EXAS Stock Details EXAS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-100	Closed	-$6K	–	203
2018 Q3	$6K	Buy	+100	New	+$6.52K	0.01%	336

Other funds holding EXAS

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return

Ballew Advisors's EXAS Position: Q4 2018 in Review

Ballew Advisors sold out of Exact Sciences (EXAS) in Q4 2018, closing a stake of 100 shares — an estimated $6K sold.

Ballew Advisors first reported a position in EXAS in Q3 2018 and held it in 1 quarter. The position peaked at $6K in Q3 2018. 370 funds tracked by Wall St. Rank hold EXAS as of Q4 2018.

Ballew Advisors reported no remaining Exact Sciences position as of Q4 2018 after selling out during the quarter.
Ballew Advisors sold 100 Exact Sciences shares in Q4 2018, an estimated $6K.
Ballew Advisors first reported a position in Exact Sciences in Q3 2018 and held it in 1 quarter.
Ballew Advisors's Exact Sciences position peaked at $6K in Q3 2018.
370 funds tracked by Wall St. Rank held Exact Sciences as of Q4 2018.

Based on Ballew Advisors's 13F filing for Q4 2018, filed 12 Feb 2019.